Gilead told NACHC in a letter yesterday it is concerned about the group's criticism of the company's new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments.

Exclusive: Gilead Responds to Health Center Group’s Criticism of its 340B Contract Pharmacy Policy

Drug manufacturer Gilead told the National Association of Community Health Centers yesterday that NACHC’s condemnation last month of Gilead’s new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments “seem to represent a misunderstanding of this integrity initiative.”

“We strongly support the work of community health centers in treating and caring for patients across the United States, and have successfully partnered in increasing access to the treatment of hepatitis C,” Gilead Vice President Jason Krings said in an April 4 letter to NACHC Interim President and CEO Rachel Gonzales-Hanson responding to her March 21 letter to the company.  “However, we are concerned with the assertions made in your recent letter.”  

Drug manufacturer Gilead told the National Association of Community Health Centers yesterday that NACHC’s condemnation last month of Gilead’s new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments “seem to represent a misunderstanding of this integrity initiative.”

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report